期刊
ONCOTARGET
卷 8, 期 17, 页码 29013-29027出版社
IMPACT JOURNALS LLC
DOI: 10.18632/oncotarget.15994
关键词
alpha 2,3-sialyltransferases type I; epidermal growth factor receptor; epithelial ovarian cancer; soyasaponin I
资金
- Ministry of Science and Technology, Executive Yuan, Taiwan [NSC 99-2314-B-010-009-MY3, NSC 102-2314- B-010-032, MOST 103-2314-B-010-043-MY3, MOST 103-2314-B-075-057-MY2]
- Taipei Veterans General Hospital [V102C-141, V102E4-003, V103E4-003, V103C-112, V104C-095, V105C-096, V106C-129, V106D23-001-MY2-1, CI-105-6]
Epithelial ovarian cancer (EOC) has the highest mortality rate among gynecologic cancers due to advanced stage presentation, peritoneal dissemination, and refractory ascites at diagnosis. We investigated the role of alpha 2,3-sialyltransferase type I (ST3GalI) by analyzing human ovarian cancer datasets and human EOC tissue arrays. We found that high expression of ST3GalI was associated with advanced stage EOC. Transwell migration and cell invasion assays showed that high ST3GalI expression enhanced migration of EOC cells. We also observed that there was a linear relation between ST3GalI expression and epidermal growth factor receptor (EGFR) signaling in EOC patients, and that high ST3GalI expression blocked the effect of EGFR inhibitors. CoImmunoprecipitation experiments demonstrated that ST3GalI and EGFR were present in the same protein complex. Inhibition of ST3GalI using a competitive inhibitor, Soyasaponin I (SsaI), inhibited tumor cell migration and dissemination in the in vivo mouse model with transplanted MOSEC cells. Further, SsaI synergistically enhanced the anti-tumor effects of EGFR inhibitor on EOC cells. Our study demonstrates that ST3GalI regulates ovarian cancer cell migration and peritoneal dissemination via EGFR signaling. This suggests alpha 2,3-linked sialylation inhibitors in combination with EGFR inhibitors could be effective agents for the treatment of EOC.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据